Long-Term Assets: The sum of all assets classified as non-current.
Allogene Therapeutics, Inc. (ALLO) had Long-Term Assets of $216.41M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-59.73M |
|
-- |
|
-- |
|
$65.19M |
|
$-65.19M |
|
$5.46M |
|
$-59.73M |
|
$-59.73M |
|
$-59.73M |
|
$-59.73M |
|
$-59.73M |
|
$-59.73M |
|
$-65.19M |
|
$-63.40M |
|
215.36M |
|
215.36M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$291.58M |
|
$82.99M |
|
|
Long-Term Assets |
$216.41M |
$507.98M |
|
$30.02M |
|
-- |
|
$92.57M |
|
$122.59M |
|
$385.39M |
|
$385.39M |
|
$385.39M |
|
218.60M |
|
| Cash Flow Statement Financials | |
$-52.93M |
|
$6.18M |
|
$13.99M |
|
$85.51M |
|
$52.75M |
|
$-32.76M |
|
$12.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.71 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-53.03M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.50% |
|
-15.50% |
|
-11.76% |
|
-15.50% |
|
$1.76 |
|
$-0.25 |
|
$-0.25 |
|